Many grey market research chemical companies sell “research grade” exemestane, a potent steroidal aromatase inhibitor. Although these are research chemicals, many people order them and use them as adjunct therapy for their steroid cycles. Exemestane is a popular ancillary drug used by steroid users on cycle or after a cycle to combat estrogen and to increase the body’s ability to boost testosterone. A new study has shown that oral exemestane may not be the best for post cycle therapy. During oral metabolism, the 17-keto group is metabolized to a 17-OH making this a full fledged androgen.
On cycle this extra androgenic boost could be a good thing, but off cycle this may prolong shut down. So, it’s important for men who use these drugs to have an idea of their activity so they can plan for the best possible use of their ancillary drugs. Although we don’t condone the use of grey market chemicals, it’s blind to think that this kind of use isn’t going on and ignore it. Better to give people the information so they can further increase their safety.
Here’s the abstract:
Ariazi EA, Leitão A, Oprea TI, Chen B Mol Cancer Ther. 2007 Nov;6(11):2817-27. Epub 2007 Nov 7.
Exemestane’s 17-hydroxylated metabolite exerts biological effects as an androgen.
Aromatase inhibitors (AI) are being evaluated as long-term adjuvant therapies and chemopreventives in breast cancer. However, there are concerns about bone mineral density loss in an estrogen-free environment. Unlike nonsteroidal AIs, the steroidal AI exemestane may exert beneficial effects on bone through its primary metabolite 17-hydroexemestane. We investigated 17-hydroexemestane and observed it bound estrogen receptor alpha (ERalpha) very weakly and androgen receptor (AR) strongly. Next, we evaluated 17-hydroexemestane in MCF-7 and T47D breast cancer cells and attributed dependency of its effects on ER or AR using the antiestrogen fulvestrant or the antiandrogen bicalutamide. 17-Hydroexemestane induced proliferation, stimulated cell cycle progression and regulated transcription at high sub-micromolar and micromolar concentrations through ER in both cell lines, but through AR at low nanomolar concentrations selectively in T47D cells. Responses of each cell type to high and low concentrations of the non-aromatizable synthetic androgen R1881 paralleled those of 17-hydroexemestane. 17-Hydroexemestane down-regulated ERalpha protein levels at high concentrations in a cell type-specific manner similarly as 17beta-estradiol, and increased AR protein accumulation at low concentrations in both cell types similarly as R1881. Computer docking indicated that the 17beta-OH group of 17-hydroexemestane relative to the 17-keto group of exemestane contributed significantly more intermolecular interaction energy toward binding AR than ERalpha. Molecular modeling also indicated that 17-hydroexemestane interacted with ERalpha and AR through selective recognition motifs employed by 17beta-estradiol and R1881, respectively. We conclude that 17-hydroexemestane exerts biological effects as an androgen. These results may have important implications for long-term maintenance of patients with AIs.